Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

PURPOSE: The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐aflibercept in routine clinical practice was evaluated. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández Montes, Ana, Martínez Lago, Nieves, Covela Rúa, Marta, de la Cámara Gómez, Juan, González Villaroel, Paula, Méndez Méndez, José Carlos, Jorge Fernández, Mónica, Salgado Fernández, Mercedes, Reboredo López, Margarita, Quintero Aldana, Guillermo, Luz Pellón Augusto, María, Graña Suárez, Begoña, García Gómez, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434192/
https://www.ncbi.nlm.nih.gov/pubmed/30690930
http://dx.doi.org/10.1002/cam4.1903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434192/
https://www.ncbi.nlm.nih.gov/pubmed/30690930
http://dx.doi.org/10.1002/cam4.1903

Ejemplares similares